Research programme: oncolytic vaccinia viruses - SillaJen Biotherapeutics

Drug Profile

Research programme: oncolytic vaccinia viruses - SillaJen Biotherapeutics

Alternative Names: JX-963; SJ 815; SJ 963

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Jennerex Biotherapeutics
  • Developer Jennerex
  • Class Oncolytic viruses
  • Mechanism of Action Epidermal growth factor receptor antagonists; Ras signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 19 Jun 2014 SillaJen is now called SillaJen Biotherapeutics
  • 17 Mar 2014 Preclinical development is ongoing in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top